Certara partners With LabLogic Systems to facilitate faster drug discovery analyses – Customers can now import ADME and protein-binding data directly from Debra to Phoenix

Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has announced that it has partnered with LabLogic Systems to integrate Certara’s Phoenix® WinNonlin® pharmacokinetic (PK)/pharmacodynamic (PD) modeling and non-compartmental analysis product with LabLogic’s Debra™ Laboratory Information Management System (LIMS). Debra is used to manage data from absorption, distribution, metabolism, and excretion (ADME) and protein-binding studies. The resulting solution, allows customers who are using Debra 6 as their LIMS for drug metabolism studies, to push their data directly into Phoenix WinNonlin.

“This integration will allow the two systems to communicate directly, thus removing the need to export data from Debra,” said Dr. Daniel Weiner, senior vice president and general manager at Certara. “It will increase system usability and should also provide quality control benefits.”

Debra can manage mass balance, tissue distribution, and PK results from ADME studies. With the addition of LabLogic’s Protein Binding module, Debra can also perform a comprehensive series of protein-binding assays.

Phoenix WinNonlin provides robust, intuitive modeling tools that allow researchers to visualise and analyse their PK and PK/PD data easily. It also enables them to collect all their results, including plots, tables and workflows, in a single project file. This convenient data management approach encourages results sharing and collaboration between team members.

“We developed this integration for Debra and Phoenix WinNonlin, two industry standard drug discovery software products, in direct response to customer requests,” said Huw Loaring, systems director at LabLogic. “We are always looking for ways to help our pharmaceutical customers to streamline their drug discovery process.”